戊型肝炎病毒IV型衣壳蛋白缺失突变体原核表达与性质

采用PCR技术扩增基因IV型HEV(Hepatitis E Virus,HEV)开放阅读框2(Open Reading Frame 2,ORF2)的缺失突变体(aa384-606),亚克隆到表达载体后,转化到大肠杆菌中进行诱导表达,表达蛋白命名为rP24。SDS-PAGE和免疫印迹实验表明,rP24获得了高效表达,且和单克隆抗体15B2具有强的反应活性。rP24经过包涵体洗涤、溶解复性、离子交换层析和分子筛层析纯化后,免疫印迹实验表明,纯化rP24能与抗HEV ORF2中和单克隆抗体8C11以及HE(Hepatitis E,HE)阳性血清发生很强的免疫反应性,说明rP24上具有构象型中和表位,模拟了HEV衣壳蛋白的空间结构。动态光散色测量结果表明,rP24的平均水化半径为7.48 nm;纯化rP24免疫动物实验表明,rP24具有强的抗原性,小鼠阳转周期短,抗体持续时间长;纯化rP24作为包被抗原检测HE阳性血清和阴性血清,结果显示rP24对HE阳性血清和阴性血清检出率与北京万泰公司的抗HEV-IgG检测试剂盒的检出率一致。这些实验结果说明,具有较好免疫反应性和免疫原性的rP24获得了高效表达,该蛋白模拟了天然病毒衣壳蛋白的中和表位,为进一步研究基因I型和基因IV型HEV感染不同宿主细胞差异的分子机制奠定了基础。     

罂粟壳成分快速检测方法在食品监督中的应用

目的：建立食品中罂粟壳成分的快速检测方法,为罂粟壳成分的检测提供依据。方法：对监督执法中抽检的20份样品中的5种罂粟壳成分应用竞争抑制免疫层析快速检测法进行检测,然后利用液相色谱—质谱法对阳性样品进行检测验证。结果：经液相色谱—质谱法和竞争抑制免疫层析法检测,20份样品中有2份检测阳性、18份阴性,合格率90%,竞争抑制免疫层析法阳性检出率100%。结论：竞争抑制免疫层析法快速、便捷,干扰因素少,阳性检出率高,值得应用推广。     

大鼠仙台病毒ELISA、间接免疫荧光和免疫印迹三种检测方法比较

目的比较ELISA（enzyme-linked immunosorbent assay）、IFA（immuno-fluorescence assay）和WB（Western blot）三种方法在大鼠仙台病毒血清学检测中的差异。方法仙台病毒蛋白抗原经凝胶电泳分离转移后用于血清学检测的WB方法;使用IFA、ELISA方法对20份无菌大鼠、227份SPF大鼠以及63份清洁级大鼠送检血清样品进行检测,阳性及可疑样品用WB方法进行了验证。结果 20份无菌大鼠血清样品被3种方法检测为仙台病毒抗体阴性;SPF级大鼠样品被IFA方法判定为阴性,1.32%（3/227）被ELISA方法判定为阳性,其中有2/3被WB确认为阳性;ELISA、IFA和WB在清洁级大鼠样品中检出仙台病毒的阳性率分别为为18.12%、11.34%和15.87%。结论三种检测方法灵敏度从高到低依次为ELISA、WB和IFA。WB方法可作为IFA和ELISA难以确定结果的替代方法。     

基因重组抗原检测梅毒螺旋体抗体研究

梅毒是一种传染性很强的性传播疾病,早期诊断是防止其传播及治疗的关键。采用基因重组的梅毒螺旋体P47和P15抗原对289份临床标本进行梅毒螺旋体抗体的检测,并与常规方法进行了比较,结果表明：重组抗原ELISA法具有较高的敏感性和特异性,并能对梅毒进行早期诊断,可以代替常规方法检测梅毒螺旋体抗体。186份现患和已治愈梅毒患者标本,重组抗原ELISA法、TPHA法和RPR法均为阳性;60份健康献血员标本,重组抗原ELISA法和TPHA法、RPR法均为阴性;17份与梅毒患者有性接触者的标本,重组抗原ELISA法有2份阳性,而TPHA法、RPR法均为阴性,1个月后复查这2份血清TPHA和RPR均为阳性;6份RPR和类风湿因子均为阳性的血清,重组抗原ELISA法和TPHA法均为阴性,;20份肝硬化患者血清,3种方法检测均为阴性。     

应用分子生物学方法检测宫颈液基细胞残液中HPV16／18感染的对比研究

对比免疫蛋白印迹及斑点杂交检测人乳头瘤病毒HPV16/18的检出率,以期找到子宫颈癌早期筛查的最佳方法。采用免疫蛋白印迹与斑点杂交分别对173份宫颈液基细胞进行HPV16/18检测。150例经宫颈液基细胞学镜下筛查为宫颈上皮内病变及宫颈癌的患者,其中免疫蛋白印迹对低度病变检出率为47.6%(30/63),对高度病变检出率为57.9%(33/57),对浸润癌的检出率为86.7%(26/30),其中鳞癌为85%(17/20),腺癌为90%(9/10),采用斑点杂交对低度病变检出率为28.6%(18/63),对高度病变检出率为42.1%(24/57),浸润癌的检出率为80%(24/30),其中鳞癌为75%(15/20),腺癌为90%(9/10)。采用免疫蛋白印迹对23例正常对照的细胞HPV检出率为13.1%(3/23),斑点杂交的检出率为8.7%(2/23)。各级宫颈病变中HPV16/18的检出率均较对照组差异有统计学意义(P<0.05)。免疫蛋白印迹检测HPV16/18比斑点杂交的检出率要高,为发现HPV一过性携带者,达到早期诊断的目的。     

应用基因重组Epstein-Barr病毒早期抗原P83蛋白检测鼻咽癌患者血清中的IgA/EA抗体

将pUCB质粒表达的P83蛋白应用于免疫印迹法(IB)和ELISA中,检测了85例鼻咽癌(NPC)患者和100例健康人血清,同时与免疫酶法(IE)作比较。结果表明,免疫印迹法对NPC患者血清阳性检出率为94％;ELISA法阳性检出率为88％;而IE法阳性率为64％。三种方法检测健康人血清出现低水平IgA/EA抗体的阳性率分别为4％、3％及2％。用IE法检测IgA/EA抗体为阴性的NPC患者血清,用IB法检测的阳性率达87％,ELISA法阳性检出率为77％。IB法与ELISA法之间具有较好的正相关(r=0.67,P<0.01)。     

婴幼儿腹泻A群轮状病毒G和P的基因分型研究

目的研究浙江萧山医院婴幼儿童腹泻标本中人轮状病毒（Human Rotavims）毒株的感染情况及G和P基因型流行特点。方法收集该院2009年8月至2010年8月腹泻儿童15233份粪便标本采用酶联免疫吸附试验、逆转录-巢式聚合酶链反应进行轮状病毒病原检测,将128份阳性标本进行VP7和VP4基本分型。结果15233份婴幼儿腹泻标本中有2706份标本为轮状病毒阳性,阳性率17．8％;男孩和女孩检出率差异无统计学意义,以6-12月龄段检出率最高;对128份阳性标本进行G血清分型和P基因分型,G1型53份（41．4％）、G3型38份（29．7％）、G1G3型17份（13．3％）、G未分型20份（15．6％）;P[8]型72份（56．3％）、P[4]型16份（12．5％）、P[8]P[4]型3份（2．3％）、P未分型37份（28．9％）,G血清型和P基因型的组合以G1P[8]为主,占29．7％（38／128）。结论浙江萧山医院A群轮状病毒G血清以G1型为主,其次为G3型,P基因型以P[8]型为主。     

同时检测血清中多种抗体的蛋白质微阵列研究

建立一种用蛋白质微阵列法可同时检测血清中艾滋病毒（HIV）, 丙型肝炎病毒（HCV）和梅毒螺旋体（TP）抗体的方法.将基因工程HIV、HCV和TP 3种融合抗原共价结合于固相载体玻片上,制成蛋白质微阵列,血清样本经稀释、加样、孵育、洗涤后,加上Cy3荧光标记二抗,洗涤,激光共聚扫描,将获得的图片用Bio-discover公司的Imagene专用分析软件进行分析,所获数据在经过自行编写的软件,根据Cutoff值自动生成判断结果.用此蛋白质微阵列系统检测了400例阴性血清,确定了Cutoff值,检测中国药品生物制品检定研究所的HIV, HCV和TP 3种参比品,并与3种ELISA试剂盒的结果进行了比较.蛋白质微阵列的艾滋病毒阳性和阴性符合率均为100%(20/20); 丙型肝炎病毒阳性和阴性符合率均为95%(38/40).梅毒螺旋体参比品阳性符合率为100%(10/10),阴性符合率为100%(20/20),蛋白质微阵列与三种ELISA试剂检测国家HIV、TP、HCV参比品（共150份血清样本）,结果具有高度的符合率.     

肺炎支原体P1重组蛋白的提取纯化及应用研究

提取纯化肺炎支原体(Mycoplasma pneumoniae,Mp)P1重组蛋白,建立酶联免疫吸附实验(ELISA)的方法,协助临床肺炎支原体感染的诊断。以GST融合蛋白层析柱提取、纯化Mp P1重组蛋白做抗原,以全肺炎支原体菌体成分做抗原对照,建立间接ELISA实验方法,检测40份正常献血者血清标本和51份疑似MP感染临床血清标本的IgG抗体。重组蛋白经SDS-PAGE可见诱导表达的样品在分子量大约59 ku处有明显条带,经Western blotting可与肺炎支原体免疫血清发生反应。ELISA实验检测51份临床标本,由P1重组蛋白抗原检测阳性31份,阳性率为60.78%。Mp检测阳性20份,阳性率为39.22%。实验精确度检测阳性混合血清的变异系数(CV值)为5.40%,阴性混合血清变异系数为1.10%。用Mp P1重组蛋白抗原建立的ELISA检测方法,其敏感性高于全肺炎支原体抗原,可用于临床肺炎支原体感染的诊断。     

应用纯化的重组Epstein-Barr病毒早期抗原建立检测鼻咽癌病人血清IgA/EA抗体的ELISA方法

利用凝胶和离子交换柱(Mono Q)两次层析,将大肠杆菌表达的EB病毒早期抗原P138片段多肽纯化。以此P138为抗原,增加鼠抗人IgA单克隆抗体以扩大IgA的反应,建立了三步ELISA法。用本法检查了100例鼻咽癌病人和63例正常人血清中抗EB病毒IgA/EA抗体,病人血清的阳性检出率为86％,正常人有3例阳性(4.7％)。此结果表明,三步ELISA法较常用的间接ELISA法(阳性检出率为71％)敏感。     

HIV—1 P24截短体与gp41截短体的融合蛋白在大肠杆菌中的表达、纯化和鉴定

用基因重组技术将截短的HIV－1 p24基因和gp41基因连接成嵌合基因,插入质粒pGEX-4T3,构建成重组表达质粒pGEX-F。将pGEX-F转化大肠杆菌BL21。经IPTG诱导表达,pGEX-F在大肠杆菌BL21中获得了高效表达。融合蛋白P24－gp41经Glutathione-Sepharose4B亲和层析纯化后,用间接ELISA和免疫印迹检测HIV抗体阳性血清和正常人血清,P24－gp41只与HIV抗体阳性血清反应,证明获得的融合蛋白P24－gp41有很强的抗原特异性和免疫反应性,具有较高的应用价值。     

Chimeric synthetic peptide as antigen for immunodiagnosis of HIV-1 infection

One chimeric peptide incorporating antigenic sequences from the gp41 transmembrane region (peptide H-18) and the gp120 envelope region (peptide H-15) corresponding to amino acids (587-617) on gp41 and (495-516) on gp120 of human immunodeficiency virus (HIV 1) was synthesized. Both sequences were separated by two glycine residues. This peptide was evaluated as antigen in an ultramicro-enzyme-linked immunosorbent assay (UMELISA) with samples derived from HIV-1 (n = 30) with different titers of antibodies and healthy blood donors (n = 30). The results were compared to plates coated with monomeric peptides and to plates coated with two monomeric peptides together. Results demonstrated that monomeric peptides gp41 (H-18) and gp120 (H-15) were good as antigens with samples that present antibodies to these regions. The chimeric peptide was the most antigenic. Those results may be related to the peptide structure, adsorption to the solid surface, and epitope accessibility to the antibodies. This chimeric peptide would be very useful for HIV-1 diagnostics.     

艾滋病血清学诊断新方法——免疫斑点法的建立

运用基因重组技术在大肠杆菌生产出有诊断意义的人免疫缺损病毒(HIV)蛋白,将其初步提纯,再用快速蛋白液相层析技术进一步纯化,即可直接点样至硝酸纤维膜,用来检测HIV抗体。实验显示,这种免疫斑点法(Immunodot assay,IDA)的敏感性与间接免疫荧光法(IIF)相同,而特异性比它高,与蛋白印迹法(WB)相近。由于IDA试剂成本比IIF低,可用于HIV抗体检测的初筛。与IIF相比,IDA法具有假阳性率低、试剂稳定性高、操作简便和不需要昂贵的荧光显微镜等优点。因而是一种适合在基层应用的方法。     

A new capture test using conjugated peptides for the detection of HIV antibodies

Abstract A new capture test utilizing conjugated peptides has been developed for the detection of antibodies elicited against HIV-1. Human sera diluted 1:1000 were incubated in ELISA plates precoated with protein G. The captured IgG were allowed to react with three synthetic peptides corresponding to the gp41 sequence (591–611) YLKDQQLLGIWGCSGKLICTT, the gp120 sequence (314–329) IRIQRGPGRAFVTIGK and the p27 sequence (182–198) EWRFDSRLAFHHVAREL. The peptides were used in the form of N -hydroxysuccinimido-biotin ovalbumin conjugates. Peroxidase-labelled streptavidin was used to detect antigen-antibody complexes. The sensitivity and specificity of detection of antibodies were analyzed with 40 HIV positive sera, 10 seroconverting sera and 21 normal human sera (NHS). The results were compared with a commercial indirect ELISA in which a single conjugated gp41 peptide was used as antigenic probe. This indirect ELISA recognized 100% of the HIV positive and the seroconverting sera. The new capture test using the gp41 conjugated peptide also recognized 100% of the HIV positive sera but was more specific since it gave no false positive results whereas the indirect test did. The gp120 and p27 conjugated peptides detected 35/40 (87.5%) and 31/40 (77.5%) of HIV positive sera respectively and also detected 9/10 (90%) and 10/10 (100%) of the seroconverting sera respectively, without any false positive results (0/21). The proposed new capture test is a very sensitive and specific assay for detecting HIV antibodies.     

A new capture test using conjugated peptides for the detection of HIV antibodies.

A new capture test utilizing conjugated peptides has been developed for the detection of antibodies elicited against HIV-1. Human sera diluted 1:1000 were incubated in ELISA plates precoated with protein G. The captured IgG were allowed to react with three synthetic peptides corresponding to the gp41 sequence (591-611) YLKDQQLLGIWGCSGKLICTT, the gp120 sequence (314-329) IRIQRGPGRAFVTIGK and the p27 sequence (182-198) EWRFDSRLAFHHVAREL. The peptides were used in the form of N-hydroxysuccinimido-biotin ovalbumin conjugates. Peroxidase-labelled streptavidin was used to detect antigen-antibody complexes. The sensitivity and specificity of detection of antibodies were analyzed with 40 HIV positive sera, 10 seroconverting sera and 21 normal human sera (NHS). The results were compared with a commercial indirect ELISA in which a single conjugated gp41 peptide was used as antigenic probe. This indirect ELISA recognized 100% of the HIV positive and the seroconverting sera. The new capture test using the gp41 conjugated peptide also recognized 100% of the HIV positive sera but was more specific since it gave no false positive results whereas the indirect test did. The gp120 and p27 conjugated peptides detected 35/40 (87.5%) and 31/40 (77.5%) of HIV positive sera respectively and also detected 9/10 (90%) and 10/10 (100%) of the seroconverting sera respectively, without any false positive results (0/21). The proposed new capture test is a very sensitive and specific assay for detecting HIV antibodies.     

An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence

Human immunodeficiency virus (HIV) type 1 infection requires functional interactions of the viral surface (gp120) glycoprotein with cell surface CD4 and a chemokine coreceptor (usually CCR5 or CXCR4) and of the viral transmembrane (gp41) glycoprotein with the target cell membrane. Extensive genetic variability, generally in gp120 and the gp41 ectodomain, can result in altered coreceptor use, fusion kinetics, and neutralization sensitivity. Here we describe an R5 HIV variant that, in contrast to its parental virus, infects T-cell lines expressing low levels of cell surface CCR5. This correlated with an ability to infect cells in the absence of CD4, increased sensitivity to a neutralizing antibody recognizing the coreceptor binding site of gp120, and increased resistance to the fusion inhibitor T-20. Surprisingly, these properties were determined by alterations in gp41, including the cytoplasmic tail, a region not previously shown to influence coreceptor use. These data indicate that HIV infection of cells with limiting levels of cell surface CCR5 can be facilitated by gp41 sequences that are not exposed on the envelope ectodomain yet induce allosteric changes in gp120 that facilitate exposure of the CCR5 binding site.     

HIV-1 Specific Antibody Titers and Neutralization among Chronically Infected Patients on Long-Term Suppressive Antiretroviral Therapy (ART): A Cross-Sectional Study

The majority of potent and broadly neutralizing antibodies against HIV-1 have been isolated from untreated patients with acute or chronic infection. To assess the extent of HIV-1 specific antibody response and neutralization after many years of virologic suppression from potent combination ART, we examined antibody binding titers and neutralization of 51 patients with chronic HIV-1 infection on suppressive ART for at least three years. In this cross-sectional analysis, we found high antibody titers against gp120, gp41, and the membrane proximal external region (MPER) in 59%, 43%, and 27% of patients, respectively. We observed significantly higher endpoint binding titers for gp120 and gp41 for patients with >10 compared to ≤10 years of detectable HIV RNA. Additionally, we observed higher median gp120 and gp41 antibody titers in patients with HIV RNA <50 copies/mL for ≤5 years. 22% of patients neutralized a HIV-1 primary isolate (HIV-1_JR-FL) and 8% neutralized a HIV-2/HIV-1 MPER chimera. Significantly greater HIV-1_JR-FL neutralization was found among patients with >10 years of detectable HIV RNA (8/20 [40.0%] versus 3/31 [9.7%] for ≤10 years, p = 0.02) and a trend toward greater neutralization in patients with ≤5 years of HIV RNA <50 copies/mL (7/20 [35.0%] versus 4/31 [12.9%] for >5 years, p = 0.08). All patients with neutralizing activity mediated successful phagocytosis of VLPs by THP-1 cells after antibody opsonization. Our findings of highly specific antibodies to several structural epitopes of HIV-1 with antibody effector functions and neutralizing activity after long-term suppressive ART, suggest continuous antigenic stimulation and evolution of HIV-specific antibody response occurs before and after suppression with ART. These patients, particularly those with slower HIV progression and more time with detectable viremia prior to initiation of suppressive ART, are a promising population to identify and further study functional antibodies against HIV-1.     

HIV-1 P24抗原国家参考品的研制

收集正常人、HIV感染者和疑似感染者血浆以及HIV-1病毒培养裂解液,对其进行HIV抗体、HIVP24抗原、HCV抗体和HBsAg检测,对HIVP24抗原阳性者进行HIVRNA检测,并对部分样品进行基因分型。以NIBSCP24抗原标准品的系列稀释样品作为线性灵敏度参考品。经过实验筛选出20份阴性参考品,10份阳性参考品,10份线性灵敏度参考品,2份精密性参考品,共同组成HIV-1P24抗原国家参考品,经多家不同的试剂进行标定,制定了相应的标准。稳定性研究结果表明,反复冻融三次对该参考品的稳定性没有影响。由此,初步建立了HIV-1P24抗原国家参考品,该参考品将对HIV-1P24抗原、HIV抗体/P24抗原联合检测试剂的质量控制提供重要依据。     

R-ELISA: repeated use of antigen-coated plates for ELISA and its application for testing of antibodies to HIV and other pathogens.

In this paper we report on the evaluation of several procedures that allow for the repeated use of an antigen-coated, enzyme-linked immunosorbent assay (ELISA) plate for enzyme immunoassay (EIA). We have shown that antigen-coated ELISA plates that were incubated once with an aqueous solution containing 8 M urea, 2% sodium dodecyl sulfate and 2% mercaptoethanol, after an EIA, can be reused again for EIA without loss of antigenic capacity. Thus, in this procedure, after an EIA, the ELISA plates were washed once with the above solution and then in a buffer containing 20 mM Tris-HCl, pH 7.5, 0.1% Tween 20 and 500 mM NaCl. This washing protocol was shown to remove the primary antibody, enzyme-conjugated secondary antibody and substrate without removing the antigen from the ELISA plate microwells. Thus, an antigen-coated ELISA plate previously used for an assay could be reused. We tested this repeat ELISA (R-ELISA) procedure on high antigen-binding ELISA plates coated with two different plant virus proteins, a synthetic peptide, the p25/24 gag and the gp120 proteins of the human immuno-deficiency virus, or the staphylococcus enterotoxin protein. In each case tested, the procedure allowed for the repeated use of the same antigen-coated plates for EIA of the respective antibodies. This procedure should prove to be particularly valuable for mass screening of samples tested for HIV and other disease-causing agents.     

人源单克隆抗人免疫缺陷病毒1型抗体Fab段基因的获得

应用噬苏体抗体库技术有效地筛选出了多株抗ＨＩＶ－１人源单克隆抗体。以逆转录聚合酶链反应（ＲＴ－ＰＣＲ）从ＨＩＶ－１感染者外周血淋巴细胞中扩增抗体轻重链可变区基因,插入载体ｐＣＯＭＢ３,建立噬菌体抗体库。分别以ＨＩＶ－１ｇｐ１２０和ｇｐ１６０为固相抗原,经过多轮筛选,从中获得了多株抗ＨＩＶ－１ｇｐ４１、ｇｐ１２０和ｇｐ１６０的单克隆抗体Ｆａｂ段基因。抗ＨＩＶ特异性噬菌体抗体随抗体库的筛选高度富集,抗